Carbamazepine (Epilepsy) updated on 04-22-2025

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17503
R73547		 Wiggs, 2024 Cleft lip and cleft palate early pregnancy population based cohort retrospective unexposed, sick Adjustment: Yes 1.51 [0.51;4.50] -/1,456   -/12,666 - 1,456
ref
S382
R16395		 Tomson (Carbamazepine), 2018 Cleft lip or palate at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 0.86 [0.14;5.13] C 2/1,957   3/2,514 5 1,957
ref
S6290
R16962		 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Facial cleft 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 2.54 [0.46;13.86] C 4/1,657   2/2,098 6 1,657
ref
S5937
R23781		 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 Oral cleft 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No Controls: mixed indications 1.08 [0.34;3.41] C 5/1,033   7/1,562 12 1,033
ref
Total 4 studies 1.35 [0.69;2.63] 23 6,103
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Wiggs, 2024Wiggs, 2024 1.51[0.51; 4.50]-1,45637%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Tomson (Carbamazepine), 2018Tomson, 2018 1 0.86[0.14; 5.13]51,95714%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014Campbell, 2014 2 2.54[0.46; 13.86]61,65715%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012Hernández-Díaz, 2012 3 1.08[0.34; 3.41]121,03333%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 0% 1.35[0.69; 2.63]236,1030.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine; 2: Carbamazepine) (Controls exposed to Lamotrigine, sick; 3: Carbamazepine) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.35[0.69; 2.63]236,1030%NAWiggs, 2024 Tomson (Carbamazepine), 2018 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 4 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.51[0.51; 4.49]-1,456 -NAWiggs, 2024 1 exposed to other treatment, sickexposed to other treatment, sick 1.27[0.55; 2.93]234,6470%NATomson (Carbamazepine), 2018 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 3 Tags Adjustment   - No  - No 1.27[0.55; 2.93]234,6470%NATomson (Carbamazepine), 2018 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 3   - Yes  - Yes 1.51[0.51; 4.49]-1,456 -NAWiggs, 2024 1 Controls   - mixed indications  - mixed indications 1.08[0.34; 3.41]121,033 -NAHernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 1 All studiesAll studies 1.35[0.69; 2.63]236,1030%NAWiggs, 2024 Tomson (Carbamazepine), 2018 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 40.210.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-2.12.41.0960.000Wiggs, 2024Tomson (Carbamazepine), 2018Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.51[0.51; 4.49]-1,456 -NAWiggs, 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.27[0.55; 2.93]234,6470%NATomson (Carbamazepine), 2018 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 30.510.01.0